凝血因子 XIII val34leu 与心肌梗死风险

Factor XIII val34leu and the risk of myocardial infarction.

作者信息

Franco R F, Pazin-Filho A, Tavella M H, Simões M V, Marin-Neto J A, Zago M A

机构信息

Laboratory of Haematology, Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, 14048-900 Ribeirão Preto - SP, Brazil.

出版信息

Haematologica. 2000 Jan;85(1):67-71.

PMID:10629595

Abstract

BACKGROUND AND OBJECTIVE

Recent studies have suggested an association between a genetic variation in the coagulation factor XIII (FXIII Val34Leu) and decreased risk of vascular thrombosis.

DESIGN AND METHODS

We investigated the frequency of the FXIII Val34Leu polymorphism in 150 consecutive, unrelated and relatively young (<55 years) survivors of myocardial infarction (MI) with angiographically-proven severe coronary atherosclerosis and in 150 age-, gender- and race-matched controls.

RESULTS

FXIII Val34Leu was detected in 54/150 patients and 73/150 controls, yielding an overall odds ratio (OR) for MI of 0.6 (CI95: 0.4-0.9). Homozygosity for FXIII Val34Leu was found in 4/150 patients and in 12/150 controls, yielding an OR for MI of 0.26 (CI95: 0.08-0.9). The OR for heterozygotes was 0.65 (CI95: 0.4-1.1). FXIII Val34Leu carriership decreased the risk of MI related to metabolic risk factors (RF) (hypertension, diabetes, dyslipidemia, and obesity): non-carriers in the presence of a metabolic RF had a 13.9-fold higher risk of MI, whereas in carriers with a metabolic RF the risk was reduced to 6.8. FXIII Val34Leu also attenuated the risk of MI among smokers. Non-carrier smokers had a 6.1-fold higher risk (CI95: 3.1-11.9), whereas the risk among smokers carrying FXIII Val34Leu was 3.9 (CI95: 1.9-8.1).

INTERPRETATION AND CONCLUSIONS

FXIII Val34Leu confers a significant protective effect against the occurrence of MI in relatively young patients. FXIII Val34Leu exhibits a gene dosage effect: the protective effect was particularly strong in homozygous carriers, and heterozygosity conferred moderate protection. Finally, FXIII Val34Leu seems to reduce the risk of MI related to major cardiovascular risk factors.

摘要

背景与目的

近期研究表明凝血因子 XIII（FXIII Val34Leu）的基因变异与血管血栓形成风险降低之间存在关联。

设计与方法

我们调查了 150 例连续的、无亲缘关系且相对年轻（<55 岁）的心肌梗死（MI）幸存者中 FXIII Val34Leu 多态性的频率，这些患者经血管造影证实患有严重冠状动脉粥样硬化，并与 150 例年龄、性别和种族匹配的对照者进行比较。

结果

在 150 例患者中有 54 例检测到 FXIII Val34Leu，150 例对照者中有 73 例检测到，MI 的总体优势比（OR）为 0.6（95%CI：0.4 - 0.9）。在 150 例患者中有 4 例为 FXIII Val34Leu 纯合子，150 例对照者中有 12 例，MI 的 OR 为 0.26（95%CI：0.08 - 0.9）。杂合子的 OR 为 0.65（95%CI：0.4 - 1.1）。FXIII Val34Leu 携带者降低了与代谢危险因素（RF）（高血压、糖尿病、血脂异常和肥胖）相关的 MI 风险：存在代谢 RF 的非携带者患 MI 的风险高 13.9 倍，而存在代谢 RF 的携带者风险降至 6.8 倍。FXIII Val34Leu 也降低了吸烟者患 MI 的风险。非携带者吸烟者的风险高 6.1 倍（95%CI：3.1 - 11.9），而携带 FXIII Val34Leu 的吸烟者风险为 3.9（95%CI：1.9 - 8.1）。